Overcoming technological and biological barriers to pulmonary mRNA delivery with lipid-polymer hybrid nanoparticles
Journal of Controlled Release · 2026-12 · 400 · 115509
DOI: 10.1016/j.jconrel.2026.115509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-12. Verfasst von Achim Biesel und 14 weiteren Autor:innen. Beteiligte Einrichtung: HIPS - Helmholtz-Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, Saarbrücken, Germany; Department of Pharmac…. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Forschung Technologie und Raumfahrt Informationstechnikzentrum Bund.
Abstract (Originalsprache)
Delivering mRNA to the lungs promises treatment of genetic, infectious and non-communicable lung diseases. Yet, conventional lipid nanoparticle formulations lack the stability needed to endure the harsh mechanical stress during nebulization. Additionally, once deposited in the respiratory tract, gene delivery systems may first have to overcome the mucus barrier, before actually transfecting the target cells. To overcome these challenges, we utilize lipid-polymer hybrid nanoparticles (LPH), merging the stability of pharmaceutical polymers with the transfection efficiency of cationic and ionizable lipids. LPH are produced in a robust microfluidic process, accomplish near-complete encapsulation efficiency, even after nebulization, and confer high transfection efficiency in A549 cells. To provide colloidal stability after aerosolization, we developed a coating strategy with hyaluronic acid (HA) and poly(vinyl alcohol) (PVA), ensuring ideal nebulization stability by steric shielding. This formulation showed good transfection efficiency of air-liquid interface grown Calu-3 cells, producing and covered by mucus. The potential of LPH to deliver mRNA to mammalian cells was first shown in primary human lung fibroblasts in vitro and could also be confirmed after intratracheal administration to mice in vivo. Together, these findings validate LPH as a versatile and aerosolizable mRNA delivery platform, overcoming the key technological and biological barriers in pulmonary gene delivery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- HIPS - Helmholtz-Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, Saarbrücken, Germany; Department of Pharmacy and PharmaScienceHub (PSH), Saarbrücken, Germany.
- Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, Hann…
- INM - Leibniz Institute for New Materials, Saarbrücken, Germany; Institute for Physical Process Technology, Saarland University of Applied Sciences, Saarbrücken, Germany.
- HIPS - Helmholtz-Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, Saarbrücken, Germany.
- Institute for Pathology, Hannover Medical School, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany; Department o…
- Institute for Pathology, Hannover Medical School, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.
Förderung
- Bundesministerium für Forschung Technologie und Raumfahrt Informationstechnikzentrum Bund
Zitieren
APA
Biesel, A., Shandheep, A., Pavlou, A., Busker, L. M., Koch, M., Kopliku, V., Maisel, K., Boese, A., Skerra, J., Schröder, L. J., Neubert, L., Schneider-Daum, N., Loretz, B., Kalinke, U., & Lehr, C. M. (2026). Overcoming technological and biological barriers to pulmonary mRNA delivery with lipid-polymer hybrid nanoparticles. Journal of Controlled Release, 400, 115509. https://doi.org/10.1016/j.jconrel.2026.115509
Vancouver
Biesel A, Shandheep A, Pavlou A, Busker LM, Koch M, Kopliku V, et al. Overcoming technological and biological barriers to pulmonary mRNA delivery with lipid-polymer hybrid nanoparticles. Journal of Controlled Release. 2026;400:115509. doi:10.1016/j.jconrel.2026.115509
BibTeX
@article{Biesel2026,
author = {Biesel, Achim and Shandheep, Aparna and Pavlou, Andreas and Busker, Lena Mareike and Koch, Marcus and Kopliku, Vesa and Maisel, Katharina and Boese, Annette and Skerra, Jennifer and Schröder, Lara-Jasmin and Neubert, Lavinia and Schneider-Daum, Nicole and Loretz, Brigitta and Kalinke, Ulrich and Lehr, Claus-Michael},
title = {Overcoming technological and biological barriers to pulmonary mRNA delivery with lipid-polymer hybrid nanoparticles},
journal = {Journal of Controlled Release},
year = {2026},
volume = {400},
pages = {115509},
doi = {10.1016/j.jconrel.2026.115509}
}
EUVIMED